Recent advances of radiofrequency ablation for early hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue SUPPL. 1, 2011, Pages 115-122

  Izumi, Namiki ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

Author keywords

Alpha fetoprotein (AFP); BCLC; CLIP; Des gamma crboxy prothrombin time (DCP); Hepatocellular carcinoma; JIS; Radiofrequency ablation; Seeding; Transarterial chemoembolization

Indexed keywords

CREATININE; DECARBOXYPROTHROMBIN; TUMOR MARKER; VASCULOTROPIN;

ARTERY INJURY; ARTIFICIAL EMBOLISM; BILE DUCT INJURY; BURN; CANCER PREVENTION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; EARLY CANCER; HEMATOTHORAX; HEMOBILIA; HEMOGLOBINURIA; HEMOPERITONEUM; HUMAN; INTESTINE INJURY; LAPAROSCOPIC SURGERY; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER RESECTION; MYOGLOBINURIA; OVERALL SURVIVAL; PNEUMOTHORAX; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; RADIOFREQUENCY ABLATION; REVIEW; SURGICAL TECHNIQUE; TRANSARTERIAL EMBOLIZATION; TUMOR SEEDING;

EID: 78650795200     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06543.x     Document Type: Review

References (97)

1. Lin SM, Lin CC, Chen WT, Chen YC, Hsu CW. Radiofrequency ablation for hepatocelular carcinoma: a prospective comparison of four radiofrequency devices. J. Vasc. Interv. Radiol. 2007; 18: 1118-25.
2. Tateishi R, Shiina S, Teratani T et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005; 103: 1201-9.
3. Yan K, Chen MH, Yang W et al. Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors. Eur. J. Radiol. 2008; 67: 334-47.
4. Teratani T, Yoshida H, Shiina S et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology 2006; 43: 1101-8.
5. Song I, Rhim H, Lim HK, Kim YS, Choi D. Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tract with the use of artificial ascites: safety and technical efficacy in 143 patients. Eur. Radiol. 2009; 19: 2630-40.
6. De Baere T, Rehim MA, Teriitheau C et al. Usefulness of guiding needles for radiofrequency ablative treatment of liver tumors. Cardiovasc. Intervent. Radiol. 2006; 29: 650-4.
7. Hirooka M, Kisaka Y, Uehara T et al. Efficacy of laparoscopic radiofrequency ablation for hepatocellular carcinoma to percutaneous radiofrequency ablation with artificial ascites. Dig. Endosc. 2009; 21: 82-6.
8. Asahina Y, Nakanishi Y, Izumi N. Laparoscopic radiofrequency ablation for hepatocellular carcinoma. Dig. Endosc. 2009; 21: 67-72.
9. Norimiya T, Seo Y, Yano Y et al. Evaluation of the therapeutic effects using MD-CT immediately after RFA for HCC. Hepatogastroenterology 2006; 53: 558-60.
10. Gallotti A, D'Onofrio M, Ruzzenente A et al. Contrast-enhanced ultrasonography (CEUS) immediately after percutaneous ablation of hepatocellular carcinoma. Radiol. Med. 2009; 114: 1094-105.
11. Kisaka Y, Hirooka M, Koizumi Y et al. Contrast-enhanced sonography with abdominal virtual sonography in monitoring radiofrequency ablation of hepatocellular carcinoma. J. Clin. Ultrasound 2010; 38: 138-44.
12. N'Kontchou G, Mahamoudi A, Aout M et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognoistic factors in 235 Western patients with cirrhosis. Hepatology 2009; 50: 1475-83.
13. Livraghi T, Meloni F, Di Stasi M et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 2008; 47: 82-9.
14. Peng ZW, Zhang YJ, Chen MS, Liang HH, Li JQ, Lau WY. Risk factors of survival after percutaneous radiofrequency ablation of hepatocellular carcinoma. Surg. Oncol. 2008; 17: 23-31.
15. Choi D, Lim HK, Rhim H et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur. Radiol. 2007; 17: 684-92.
16. Kobayashi M, Ikeda K, Kawamura Y et al. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 2009; 115: 571-80.
17. Takahashi S, Kudo M, Chung H et al. PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy. Oncology 2008; 75S: 91-8.
18. Ogawa C, Kudo M, Minami Y, Chung H, Kawasaki T. Tumor markers after radiofrequency ablation therapy for hepatocellular carcinoma. Hepatogastroenterology 2008; 55: 1454-7.
19. Du XL, Ma QJ, Wu T, Baqo GQ, Lu JG, Chu YK. Significance of alpha-fetoprotein mRNA level in hepatocellular carcinoma patients treated with radiofrequency ablation. Hepatobiliary Pancreat. Dis. Int. 2007; 6: 172-5.
20. Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann. Surg. Oncol. 2007; 14: 1835-45.
21. Grieco A, Pompili M, Camitiniti G et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005; 54: 411-8.
22. Yamagiwa K, Shiraki K, Yamamoto K et al. Survival rates according to the cancer of the Italian program score of 345 hepatocellular carcinoma patients after multimodality treatments during a 10-year period in a retrospective study. J. Gastroenterol. Hepatol. 2008; 23: 482-90.
23. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J. Gastroenterol. 2003; 38: 207-15.
24. Kudo M, Chung H, Haji S et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004; 40: 1396-405.
25. Lee JH, Han SY, Jo JH et al. Prognostic factors for survival in patients with hepatocellular carcinoma after radiofrequency ablation. Korean J. Gastroenterol. 2007; 49: 17-23.
26. Takahashi S, Kudo M, Chung H et al. Initial treatment response is essential to improve survival in patients with hepatocllular carcinoma who underwent curative radiofrequency ablation therapy. Oncology 2007; 72S: 98-103.
27. Liu CH, Arellano RS, Upport RN, Samir AE, Gervais DA, Mueller PR. Radiofrequency ablation of hepatic tumours: effect of post-ablation margin on local tumour progression. Eur. Radiol. 2010; 20: 877-85.
28. Lam VW, Ng KK, Chok KS et al. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J. Am. Coll. Surg. 2008; 207: 20-9.
29. Lam VW, Ng KK, Chok KS et al. Imcomplete ablation after radiofrequency ablation of hepatocellular carcinoma: analysis of risk factors and prognostic factors. Ann. Surg. Oncol. 2008; 15: 782-90.
30. Pitton MB, Herber S, Raab P et al. Percutaneous radiofrequency ablation of liver tumors using the LeVeen 4 cm array probe. Rofo 2003; 175: 1525-31.
31. Okuwaki Y, Nakazawa T, Shibuya A et al. Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns. J. Gastroenterol. 2008; 43: 71-8.
32. Izumi N, Asahina Y, Noguchi O et al. Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. Cancer 2001; 91: 949-56.
33. Ng KK, Poon RT, Lo CM, Yuen J, Tso WK, Fan ST. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J. Gstrointest. Surg. 2009; 12: 183-91.
34. Izumi N, Asahina Y, Tsuchiya K et al. Repeated radiofrequency ablation for the distant recurrence in the liver in patients with chronic hepatitis C virus infection achieving long-term survival. Hepatol. Res. 2007; 37S2: S254-63.
35. Yamashiki N, Yoshida H, Tateishi R et al. Recurrent hepatocellular carcinoma has an increased risk of subsequent recurrence after curative treatment. J. Gastroenterol. Heapatol. 2007; 22: 2155-60.
36. Kim SH, Lim HK, Choi D et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma: effect of histologic grade on therapeutic results. Am. J. Roentgenol. 2006; 186: S327-33.
37. Kudo M, Sakaguchi Y, Chung H et al. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology 2007; 72S: 132-8.
38. Kuzuya T, Katano Y, Kumada T et al. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2007; 22: 1929-35.
39. Yoshida H, Yoshida H, Goto E et al. Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatits B viru-related hepatocellular carcinoma. Hepatol. Int. 2008; 2: 89-94.
40. Kakizaki S, Sohara N, Sato K et al. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J. Gastroenterol. Hepatol. 2007; 22: 518-22.
41. Ishikawa T, Michitaka I, Kamimura H et al. Oral branched-chain amino acids administration improves impaired liver dysfunction after radiofrequency ablation therapy for hepatocellular carcinoma. Hepatogastroenterology 2009; 56: 1491-5.
42. Lu MD, Kuang M, Liang LJ et al. Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trail. Zhonghua Yi Xue Za Zhi 2006; 28: 801-5.
43. Chen MS, Li JQ, Zheng Y et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann. Surg. 2006; 243: 321-8.
44. Guglielmi A, Ruzzenente A, Valdgegamberi A et al. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J. Gastrointest. Surg. 2008; 12: 192-8.
45. Hong SN, Lee SY, Choi MS et al. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J. Clin. Gastroenterol. 2005; 39: 247-52.
46. Santambrogio R, Opocher E, Zuin M et al. Surgical resection versus laparoscopic radiofrequency ablation in patients with hepatocelllar carcinoma and child-pugh class A liver cirrhosis. Ann. Surg. Oncol. 2009; 16: 3289-98.
47. Montorsi M, Santambrogio R, Bianchi P et al. Survival and recurrences after hepatic resection or radiofrequency for hepatocellular carcinoma in cirrhotic patients: a multivariate analysis. J. Gastrointest. Surg. 2005; 9: 62-7.
48. Abu-Hilal M, Primrose JN, Casaril A, McPhail MJ, Pearce NW, Nicoli N. Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. J. Gastroenterol. Surg. 2008; 12: 1521-6.
49. Molinari M, Helton S. Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: a Markov model decision analysis. Am. J. Surg. 2009; 198: 396-406.
50. Vivarelli M, Guglielmi A, Ruzzenente A et al. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann. Surg. 2004; 240: 102-7.
51. Ohmoto K, Yoshioka N, Tomiyama Y et al. Radiofrequency ablation versus percutaneous microwave coagulation therapy for small hepatocellular carcinomas: a retrospective comparative study. Hepatogastroenteology 2007; 54: 985-9.
52. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤ 4 cm. Gastroenterology 2004; 127: 1714-23.
53. Shiina S, Teratani T, Obi S et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122-30.
54. Iwata K, Sohda T, Nishizawa S et al. Postoperative recurrence in hepatocellular carcinoma: comparison between percutanepus ethanol injection and radiofrequency ablation. Hepatol. Res. 2006; 36: 143-8.
55. Brunello F, Veltri A, Carucci P et al. Radiofrequency ablation versusu ethanol injection for early hepatoclellular carcinoma: a randomized controlled trial. Scand. J. Gastroenterol. 2008; 43: 727-35.
56. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systemic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009; 49: 453-9.
57. Bouza C, Lopez-Cuadrado T, Alcazar R, Saz-Parkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol. 2009; 9: 31.
58. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M. Radiofrequency thermal ablation vs. Percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am. J. Gastroenterol. 2009; 104: 514-24.
59. Zhang YJ, Liang HH, Chen MS et al. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology 2007; 244: 599-607.
60. Kirikoshi H, Saito S, Yoneda M et al. Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocelllar carcinoma. Hepatol. Res. 2009; 39: 553-62.
61. Peng ZW, Chen MS, Liang HH et al. A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Eur. J. Surg. Oncol. 2010; 36: 257-63.
62. Gadaleta C, Catino A, Ranieri G et al. Single-step therapy-feasibility and safety of simultaneous transarterial chemoembolization and radiofrequency ablation for hepatic malignancies. In Vivo 2009; 23: 813-20.
63. Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur. Radiol. 2006; 16: 661-9.
64. Yamakado K, Nakatsuka A, Takaki H et al. Subphrenic versus nonsubphrenic hepatocellular carcinoma: combined therapy with chemoembolization and radiofreqeuency ablation. Am. J. Roentgenol. 2010; 194: 530-5.
65. Maluccio M, Covey AM, Gandhi R et al. Comparison of survival rates after bland arterilal embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. J. Vasc. Interv. Radiol. 2005; 16: 955-61.
66. Yamazaki T, Kimura T, Kurokawa F et al. Percutaneous radiofrequency ablation with cooled electrodes combined with hepatic arterial balloon occlusion in hepatocellular carcinoma. J. Gastroenterol. 2005; 40: 171-8.
67. Shiraishi R, Yamasaki T, Saeki I et al. Pilot study of combination therapy with transcatheter arterial infusion chemotherapy using iodized oil and percutaneous radiofrequency ablation during occlusion of hepatic blood flow for hepatocelluar carcinoma. Am. J. Clin. Oncol. 2008; 31: 311-6.
68. Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology 2009; 252: 905-13.
69. Kasugai H, Osaki Y, Oka H, Kudo M, Seki T. Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3891 ablations in 2614 patients. Oncology 2007; 72 (Suppl. 1): 72-5.
70. Kong WT, Zhang WW, Qui YD et al. Major complications after radiofrequency ablation for liver tumors: analysis of 255 patients. World J. Gastroenterol. 2009; 15: 2651-6.
71. Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann. Surg. Oncol. 2000; 7: 593-600.
72. Rhim H, Yoon KH, Lee JM et al. Major complications after radio-freqeuncy thermal ablation of hepatic tumors: a spectrum of imaging findings. Radiographics 2003; 23: 123-34.
73. De Baere T, Risse O, Kuoch V et al. Adverse events during radiofrequency treatment of 582 hepatic tumors. Am. J. Roentgenol. 2003; 181: 695-700.
74. Choi D, Lim HK, Kim MJ et al. Liver abscess after percutaneous radiofrequency ablation for hepatocellular carcinomas: frequency and risk factors. Am. J. Roentgenol. 2005; 184: 1860-7.
75. Elias D, Pietroantonio D, Gachot B, Menegon P, Hakime A, De Baere T. Liver abscess after radiofrequency ablation of tumors in patients with a biliary tract procedure. Gastroenterol. Clin. Biol. 2006; 30: 823-7.
76. Shibata T, Yamamoto Y, Yamamoto N et al. Cholangitis and liver abscess after percutaneous ablation therapy for liver tumors: incidence and risk factors. J. Vasc. Interv. Radiol. 2003; 14: 1535-42.
77. Jensen MC, van Duijnhoven FH, van Hellegersberg R et al. Adverse effects of radiofrequency ablation of liver tumors in the Netherlands. Br. J. Surg. 2005; 92: 1248-54.
78. Ohnishi T, Yasuda I, Nishigaki Y et al. Intraductal chilled saline perfusion to prevent bile duct injury during percutaneous radiofrequency ablation for hepatocellular carcinoma. J. Gastrenterol. Hepatol. 2008; 23: 410-5.
79. Goto E, Tateishi R, Shiina S et al. Hemorrhagic complications of percutaneous radiofrequency ablation for liver tumors. J. Clin. Gastroenterol. 2010; 44: 374-80.
80. Poggi G, Riccardi A, Quaretti P et al. Complications of percutaneous radiofrequency thermal ablation of primary and secondary lesions of the liver. Anticancer Res. 2007; 27: 2911-6.
81. Sartori S, Tombesi P, Macario F et al. Subcapsular liver tumors treated with percutaneous radiofrequency ablation: a prospective comparison with nonsubcapsular liver tumors for safety and effectiveness. Radiology 2008; 248: 670-9.
82. Kim YJ, Raman SS, Yu NC, Busuttil RW, Tong M, Lu DS. Radiofrequency ablation of hepatocellular carcinoma: can subcapsular tumors be safely ablated? Am. J. Roentgenol. 2008; 190: 1029-34.
83. Yeung YP, Hui J, Yip WC. Delayed colonic perforation after percutaneous radiofrequency ablation of hepatocellular carcinoma. Surg. Laparosc. Endosc. Percutan. Tech. 2007; 17: 342-4.
84. Meloni MF, Goldberg SN, Moser V, Piazza G, Livraghi T. Colonic perforation and abscess following radiofrequency ablation of hepatoma. Eur. J. Ultrasound 2002; 15: 73-6.
85. Chan FS, Ng KK, Poon RT, Yuen J, Tso WK, Fan ST. Duodenopleural fistula formation after percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma. Asian J. Surg. 2007; 30: 278-82.
86. Kim YS, Rhim H, Lim HK, Choi D, Lee WJ, Kim SH. Hepatic infarction after radiofrequency ablation of hepatocellular carcinoma with an internally cooled electrode. J. Vasc. Interv. Radiol. 2007; 18: 1126-33.
87. Zheng RQ, Kudo M, Inui K et al. Transient portal vein thrombosis caused by radiofrequency ablation for hepatocellular carcinoma. J. Gastroenterol. 2003; 38: 101-3.
88. Llovet JM, Vilana R, Bru C et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001; 33: 1124-9.
89. Livraghi T, Lazzaroni S, Meloni F, Solbiati L. Risk of tumour seeding after percutaneous radiofrequency ablation for hepatocellular carcinoma. Br. J. Surg. 2005; 92: 856-8.
90. Imamura J, Tateishi R, Shiina S et al. Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma. Am. J. Gastroenterol. 2008; 103: 3057-62.
91. Giorgia A, Tarantino L, de Stafano G, Coppola C, Ferraioli G. Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors: 3-year experience with 336 patients at a sigle center. Am. J. Roentgenol. 2005; 184: 207-11.
92. Latteri F, Sandonato L, Di Marco V et al. Seeding after radiofreqeuncy ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. Dig. Liver Dis. 2008; 40: 684-9.
93. Shankar S, van Sonnenberg E, Silverman SG, Tuncali K, Morrison PR. Management of pneumothorax during percutaneous radiofrequency ablation of a lung tumor: technical note. J. Thorac. Imaging 2003; 18: 106-9.
94. Rodriguez J, Tellioglu G, Siperstein A, Berber E. Myoglobinuria after laparoscopic radiofrequency ablation of liver tumors. J. Gastrointest. Surg. 2010; 14: 664-7.
95. Tsui SL, Lee AK, Lui SK, Poon RT, Fan ST. Acute intraoperative hemolysis and hemoglobinuria during radiofrequency ablation of hepatocellular carcinoma. Hepatogastroenterology 2003; 50: 526-9.
96. Seki T, Tamai T, Ikeda K et al. Rapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percutaneous radiofrequency ablation in the primary tumour region. Eur. J. Gastroenterol. Hepatol. 2001; 13: 291-4.
97. Zavaglia C, Corso R, Rampoldi A et al. Is percutaneous radiofrequency thermal ablation of hepatocellular carcinoma a safe procedure? Eur. J. Gastroenterol. Hepatol. 2008; 20: 196-201.